Last reviewed · How we verify

olmesartan medoxomil / amlodipine or azelnidipine

COLM Study Research Organization · FDA-approved active Small molecule

olmesartan medoxomil / amlodipine or azelnidipine is a Angiotensin II receptor blocker / Calcium channel blocker combination Small molecule drug developed by COLM Study Research Organization. It is currently FDA-approved for Hypertension.

This combination lowers blood pressure by blocking angiotensin II receptors (olmesartan medoxomil) and calcium channels (amlodipine or azelnidipine) to relax blood vessels.

Olmesartan medoxomil/amlodipine or azelnidipine is a fixed-dose combination antihypertensive marketed by the COLM Study Research Organization, combining an angiotensin II receptor blocker (ARB) with a calcium channel blocker (CCB) to provide dual-pathway blood pressure reduction. The combination leverages olmesartan's selective AT1 receptor antagonism with amlodipine's or azelnidipine's L-type calcium channel inhibition, offering complementary mechanisms for enhanced BP control in hypertensive patients. Approved for hypertension management, the drug has been evaluated in two Phase 4 trials (COLM and OSCAR studies) enrolling over 6,000 patients, demonstrating efficacy in high-risk elderly populations with cardiovascular disease and diabetes comorbidities. Clinical differentiation centers on the synergistic antihypertensive effect of ARB+CCB combinations versus monotherapy, with particular utility in patients requiring intensive BP control or those intolerant to single agents. Commercial significance remains limited to research and institutional settings given the COLM Study Research Organization's academic sponsorship; no major pharmaceutical company commercialization or significant revenue data are publicly available. The combination represents a rational polypharmacy approach supported by contemporary hypertension guidelines, though market penetration depends on regulatory approval status and manufacturing partnerships outside the research domain.

At a glance

Generic nameolmesartan medoxomil / amlodipine or azelnidipine
SponsorCOLM Study Research Organization
Drug classAngiotensin II receptor blocker / Calcium channel blocker combination
TargetAngiotensin II type 1 receptor (AT1R); L-type voltage-gated calcium channels
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) that prevents vasoconstriction and sodium retention. Amlodipine and azelnidipine are dihydropyridine calcium channel blockers that relax vascular smooth muscle. Together, they provide complementary antihypertensive effects through different mechanisms.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about olmesartan medoxomil / amlodipine or azelnidipine

What is olmesartan medoxomil / amlodipine or azelnidipine?

olmesartan medoxomil / amlodipine or azelnidipine is a Angiotensin II receptor blocker / Calcium channel blocker combination drug developed by COLM Study Research Organization, indicated for Hypertension.

How does olmesartan medoxomil / amlodipine or azelnidipine work?

This combination lowers blood pressure by blocking angiotensin II receptors (olmesartan medoxomil) and calcium channels (amlodipine or azelnidipine) to relax blood vessels.

What is olmesartan medoxomil / amlodipine or azelnidipine used for?

olmesartan medoxomil / amlodipine or azelnidipine is indicated for Hypertension.

Who makes olmesartan medoxomil / amlodipine or azelnidipine?

olmesartan medoxomil / amlodipine or azelnidipine is developed and marketed by COLM Study Research Organization (see full COLM Study Research Organization pipeline at /company/colm-study-research-organization).

What drug class is olmesartan medoxomil / amlodipine or azelnidipine in?

olmesartan medoxomil / amlodipine or azelnidipine belongs to the Angiotensin II receptor blocker / Calcium channel blocker combination class. See all Angiotensin II receptor blocker / Calcium channel blocker combination drugs at /class/angiotensin-ii-receptor-blocker-calcium-channel-blocker-combination.

What development phase is olmesartan medoxomil / amlodipine or azelnidipine in?

olmesartan medoxomil / amlodipine or azelnidipine is FDA-approved (marketed).

What are the side effects of olmesartan medoxomil / amlodipine or azelnidipine?

Common side effects of olmesartan medoxomil / amlodipine or azelnidipine include Dizziness, Headache, Peripheral edema, Fatigue, Hyperkalemia.

What does olmesartan medoxomil / amlodipine or azelnidipine target?

olmesartan medoxomil / amlodipine or azelnidipine targets Angiotensin II type 1 receptor (AT1R); L-type voltage-gated calcium channels and is a Angiotensin II receptor blocker / Calcium channel blocker combination.

Related